We provide you with 20 years of free, institutional-grade data for CNTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CNTX. Explore the full financial landscape of CNTX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about CNTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Context Therapeutics Inc.(NASDAQ:CNTX) 
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resis...
Website: http://www.contexttherapeutics.com
Founded: 2015
CEO: Martin Lehr
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends